Do they out-license AD-214 or do they co-develop? That is the question.
If the CEO's comment from BIO24 is any guide, the partnership pathway appears to have the inside running. The buzz words are 'material advancement' of the AD-214/AdSolis partnering strategy. So what would a material advancement look like in practical terms. Its certainly not the initiation of discussions but more like substantive moves towards a deal or transaction.
Of course, the co-development pathway may win out in the final straight but a good partnership deal will enable management to focus upon the next big event. AdCella will facilitate the best of innovative Asian cellular immunotherapy from east to west.
1AD Price at posting:
2.6¢ Sentiment: Buy Disclosure: Held
